wrist laser therapy equipment laser therapeutic device
Negotiable /Set
Min.Order:1 Set
Hubei YJT Technology Co., Ltd.
home use health care product for hypertention laser therapy equipment
wrist type laser therapy instrument for high blood pressure therapy
HNC HY30-D WRIST Rehabilitation Therapy Laser Products on Alibaba
Newest HNC HY30-D Rehabilitation Therapy Laser Products on Alibaba
Lower Blood Pressure Watch Rehabilitation Therapy Equipment new products to commercialize
Lower Blood Sugar Rehabilitation Therapy Equipment hot product 2013
wrist laser therapy equipment laser therapeutic device
Technical parameter:
1.) Laser medium : GaAlAs Semiconductor
2.) Laser wavelength: 650nm
3.) Terminate laser medium quantity : 6pcs.
4.) single laser medium terminate output voltage :≤5mw
5.) Terminate output laser control :3 grade for adjustment.
6.) Fixed time range: 10 minutes to 60minutes, and six grade for adjustment.
7.) Battery voltage: 3.7 to 4.2V
8.) Lithium ion battery output voltage:5.5V
9.) Instrument power consumption:<1 W
10.) Environment temperature:5-40
11.)Relative humidity: ≤80%
12.) atmospheric pressure:860kpa-1060kpa
Application Range:
Hyperviscosity, hyperlipemia, hyperlipidemia, hypertension, diabetes, ischemic heart and cerebral vascular disease caused by ischemic cardiovascular and cerebrovascular diseases. Besides, it`s also has good curative on the rhinitis, allergic rhinitis, acute rhinitis, chronic rhinitis, sinusitis and nasal polyps.
Function and Performance:
7) Improving blood viscosity through laser blood irradiation.
8) Improving blood oxygen carrying capacity through laser blood irradiation.
9) Reducing blood-fat and total cholesterol through laser blood irradiation.
10) Quickly and effectively correct the abnormity of lipid metabolism and maintain the equilibrium level of the lipid metabolism in the human body through laser blood irradiation.
11) Improving the partial blood circulation around the nasal cavities and the immunological competence of the nasal mucosa membranes through irradiation the nasal mucosa.
12) Therapeutic efficacy control on ischemic cardio-cerebrovascular diseases.